First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

NCT04083534 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions

DRUG: REGN5459

Sponsor

Regeneron Pharmaceuticals